Semaglutide (Wegovy/Ozempic) shows heart-protective benefits independent of weight loss, reducing cardiovascular event risks. Research suggests anti-inflammatory effects and impact on epicardial adipose tissue.
Research on mice reveals how CREs near the FTO locus influence metabolism, obesity, and neuroprotection during torpor. Findings could offer insights into human metabolic disorders and neuroprotective strategies.
Study shows BMI is unreliable for predicting mortality risk. Body fat percentage is a better indicator. This impacts obesity treatment access, challenging current BMI-based guidelines. BIA is more accurate.
